Evidence map›Paper›PMID 27105443›Full record

SynthesisHuman vaccines & immunotherapeutics2016

Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).

Giuseppe La Torre, Alice Mannocci, Rosella Saulle, Vittoria Colamesta, Angela Meggiolaro, Daniele Mipatrini, Alessandra Sinopoli

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Updated epidemiology of gastrointestinal cancers in East Asia.Nature reviews. Gastroenterology & hepatology · 2023
    Review
  3. Review
  4. Review
  5. The changing epidemiology of liver diseases in the Asia-Pacific region.Nature reviews. Gastroenterology & hepatology · 2019
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Giuseppe La Torrea Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Alice Mannoccia Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Rosella Saullea Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Vittoria Colamestaa Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Angela Meggiolaroa Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Daniele Mipatrinia Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Alessandra Sinopolia Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo conduct a systematic review of the economic evaluations (EE) of HBV vaccination, taking also into account the studies published in the new millennium.

methodsAn extensive scientific literature review was conducted using two electronic medical journal databases: Scopus and PubMed engines for published studies on EE of HBV vaccination.

results22 articles were reviewed, 9, 5 and 8 cost-effectiveness, cost-benefit and cost-utility analysis, respectively. Studies were mainly concerning EE of universal vaccination (UV), mostly with regards to low or low-medium income countries. For high income countries, EE were focused on the possible implementation of HBV vaccination in particular settings, such as diabetic, renal and other chronic conditions care, as well as infectious diseasesUV has usually a very good cost-effectiveness ratio (80%), ranging from cost-saving (China) or few Euro per LY/QALY gained (in Thailand, and Vietnam) to 630.00$/QALY in USA (Asian and Pacific Islands) Moreover, EE of HBV vaccination are favorable in the infectious diseases field as well as for chronic conditions. In relation to diabetes the studies gave controversial results.

conclusionThis systematic review highlighted the importance of introducing HBV vaccination not only for infant UV program but also for other settings in which patients are people affected by communicable and non-communicable diseases.

Indexed as

Cost-Benefit AnalysisCost of IllnessGlobal HealthHepatitis BHepatitis B VaccinesHumansHepatitis B Vaccinescost benefitcost-effectivenesscost-utilityeconomic evaluationHBV vaccination

Identifiers

PMID27105443
PMCPMC5027710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.